Michael S Valerio1, Bethany A Herbert2, Dimitrios S Basilakos3, Courtney Browne4, Hong Yu5, Keith L Kirkwood6. 1. Department of Oral Health Sciences and the Center for Oral Health Sciences, Medical University of South Carolina, Charleston, SC, USA. Electronic address: valeriom@musc.edu. 2. Department of Oral Health Sciences and the Center for Oral Health Sciences, Medical University of South Carolina, Charleston, SC, USA. Electronic address: herbertb@musc.edu. 3. Department of Oral Health Sciences and the Center for Oral Health Sciences, Medical University of South Carolina, Charleston, SC, USA. Electronic address: basilako@musc.edu. 4. Department of Oral Health Sciences and the Center for Oral Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 5. Department of Oral Health Sciences and the Center for Oral Health Sciences, Medical University of South Carolina, Charleston, SC, USA. Electronic address: yuho@musc.edu. 6. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. Electronic address: klkirk@musc.edu.
Abstract
UNLABELLED: Osteoclast (OC) progenitors (OCP) have been defined in the bone marrow (BM) as CD3(-)CD45R(B220)(-)GR1(-)CD11b(lo/)(-)CD115(+) (dOCP) and more recently in the peripheral blood (PB) as Lym(-)Ly6G(-)CD11b(+)Ly6C(+). These progenitors respond to stimuli, including LPS from periopathogenic Aggregatibacter actinomycetemcomitans, activating MAPK signaling, resulting in cytokine/chemokine-mediated osteoclastogenesis. Intracellular negative signaling pathways, including MAPK phosphatase-1 (MKP-1, gene Dusp1) deactivate MAPK pathways (p-p38 and p-JNK) and reduce inflammatory cytokines/chemokines. OBJECTIVE: To delineate the role of MKP-1 in chemokine-mediated OC formation using defined OC progenitor populations. Given its role in innate immune inflammatory signaling, we hypothesize that MKP-1 regulates LPS-induced OC formation from BM OCP through deregulated chemokines. METHODS: BM and PB from WT and Dusp1(-/-) female mice (8-12weeks) was obtained and sorted into defined progenitor populations. BM sorted dOCP were primed with MCSF and RANKL (48h), blocked with vehicle or chemokine blocking antibodies and stimulated with LPS (48-96h). TRAP assay and OC activity were measured for OC formation and activity following treatments. NanoString Array and qPCR were utilized for gene expression analysis. RESULTS: Dusp1(-/-) dOCPs formed more and larger osteoclasts from CD11b(hi) and dOCP compared to matched WT (P<0.05 each). PB-derived dOCP produced larger and more functional osteoclasts from Dusp1(-/-) mice compared to WT controls. NanoString array data revealed significant deregulation in chemokine expression from Dusp1(-/-) versus WT cells. qPCR validation of target genes revealed that Dusp1 deficient CD11b(+) populations display 1.5-3.5-fold greater expression of CXCL1 and 2-3-fold greater expression of CXCL2 compared to WT in CD11b(hi) and dOCP (P<0.05 each). Antibody blocking studies using anti-CXCL1 and CXCL2 antibodies blunted osteoclastogenesis in Dusp1(-/-) cells. CONCLUSION: MKP-1 negatively regulates chemokine-driven OC formation and subsequent bone resorption in response to LPS stimulation. Collectively, these data provide useful insight into mechanisms potentially leading to the development of therapeutic treatment of periodontal disease.
UNLABELLED: Osteoclast (OC) progenitors (OCP) have been defined in the bone marrow (BM) as CD3(-)CD45R(B220)(-)GR1(-)CD11b(lo/)(-)CD115(+) (dOCP) and more recently in the peripheral blood (PB) as Lym(-)Ly6G(-)CD11b(+)Ly6C(+). These progenitors respond to stimuli, including LPS from periopathogenic Aggregatibacter actinomycetemcomitans, activating MAPK signaling, resulting in cytokine/chemokine-mediated osteoclastogenesis. Intracellular negative signaling pathways, including MAPK phosphatase-1 (MKP-1, gene Dusp1) deactivate MAPK pathways (p-p38 and p-JNK) and reduce inflammatory cytokines/chemokines. OBJECTIVE: To delineate the role of MKP-1 in chemokine-mediated OC formation using defined OC progenitor populations. Given its role in innate immune inflammatory signaling, we hypothesize that MKP-1 regulates LPS-induced OC formation from BM OCP through deregulated chemokines. METHODS: BM and PB from WT and Dusp1(-/-) female mice (8-12weeks) was obtained and sorted into defined progenitor populations. BM sorted dOCP were primed with MCSF and RANKL (48h), blocked with vehicle or chemokine blocking antibodies and stimulated with LPS (48-96h). TRAP assay and OC activity were measured for OC formation and activity following treatments. NanoString Array and qPCR were utilized for gene expression analysis. RESULTS:Dusp1(-/-) dOCPs formed more and larger osteoclasts from CD11b(hi) and dOCP compared to matched WT (P<0.05 each). PB-derived dOCP produced larger and more functional osteoclasts from Dusp1(-/-) mice compared to WT controls. NanoString array data revealed significant deregulation in chemokine expression from Dusp1(-/-) versus WT cells. qPCR validation of target genes revealed that Dusp1 deficient CD11b(+) populations display 1.5-3.5-fold greater expression of CXCL1 and 2-3-fold greater expression of CXCL2 compared to WT in CD11b(hi) and dOCP (P<0.05 each). Antibody blocking studies using anti-CXCL1 and CXCL2 antibodies blunted osteoclastogenesis in Dusp1(-/-) cells. CONCLUSION:MKP-1 negatively regulates chemokine-driven OC formation and subsequent bone resorption in response to LPS stimulation. Collectively, these data provide useful insight into mechanisms potentially leading to the development of therapeutic treatment of periodontal disease.
Authors: David S Bischoff; Taylor Sakamoto; Kenji Ishida; Nalini S Makhijani; Helen E Gruber; Dean T Yamaguchi Journal: Bone Date: 2010-09-24 Impact factor: 4.398
Authors: Christian E Jacome-Galarza; Sun-Kyeong Lee; Joseph A Lorenzo; Hector Leonardo Aguila Journal: J Bone Miner Res Date: 2013-05 Impact factor: 6.741
Authors: Muzaffer Cicek; Anne Vrabel; Catherine Sturchio; Larry Pederson; John R Hawse; Malayannan Subramaniam; Thomas C Spelsberg; Merry Jo Oursler Journal: PLoS One Date: 2011-03-14 Impact factor: 3.240
Authors: Keith L Kirkwood; Lixia Zhang; Ramkumar Thiyagarajan; Kenneth L Seldeen; Bruce R Troen Journal: Immunol Invest Date: 2018-11 Impact factor: 3.657
Authors: Jan Korbecki; Iwona Szatkowska; Patrycja Kupnicka; Wojciech Żwierełło; Katarzyna Barczak; Iwona Poziomkowska-Gęsicka; Jerzy Wójcik; Dariusz Chlubek; Irena Baranowska-Bosiacka Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208
Authors: M S Valerio; D S Basilakos; J E Kirkpatrick; M Chavez; J Hathaway-Schrader; B A Herbert; K L Kirkwood Journal: J Periodontal Res Date: 2016-08-11 Impact factor: 4.419